Allt inom IR

Nanexa publishes interim report for January-March 2026

Opened the year with strong preclinical results for once-monthly and quarterly dosing of semaglutide

Nanexa resolves on set-off of outstanding loan

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION, OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. FURTHER RESTRICTIONS APPLY.